JN.1: The new COVID-19 variant of concern? by Ruby Dhar, Hiya Aidasani, Om Saswat Sahoo, Arun Kumar, Subhradip Karmakar

Subjects: “…jn.1; covid-19; spike proteins; ba.2.86; transmissibility…”
Get full text

Detection of SARS-CoV-2 BA.2.86 by lateral flow devices by Abbie Bown, Angela Sweed, Matthew Catton, Joshua Nelthorpe-Cowne, Hermione Conti-Frith, Ruth Elderfield, Jacob Terrey, Hamsa Abib, Caleb Lui, Ella Fisher, Kevin R. Bewley, Naomi S. Coombes, Donna Robinson, Somya Agrawal, Bassam Hallis, Edward Blandford, Tom Fowler, Deborah A. Williamson, Richard Vipond

Subjects: Get full text

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1 by Yanping Hu, Jing Zou, Chaitanya Kurhade, Xiangxue Deng, Hope C. Chang, Debora K. Kim, Pei-Yong Shi, Ping Ren, Xuping Xie

Subjects: Get full text

The SARS-CoV-2 BA.2.86 subvariant: A new challenge in the ongoing pandemic by Prakasini Satapathy, Ahmad Neyazi, Abdul Qadir Qader, Ali A. Rabaan, Nawal A. Al Kaabi, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin

Subjects: “…SARS-CoV-2 BA.2.86…”
Get full text

SARS-CoV-2 JN.1 variant: a short review by Sarkar Malay, Irappa V. Madabhavi, Anurag Tripathi

Subjects: Get full text

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial by Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin

Subjects: “…BA.2.86…”
Get full text

Surveillance of SARS-CoV-2 variants in Henan, China from 2023 to 2024 by Yun Song, Bicong Wu, Hongxia Ma, Yafei Li, Su Yan, Jingjing Pan, Haifeng Wang, Ying Ye, Xueyong Huang, Wanshen Guo

Subjects: Get full text

T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects by Irene Segato, Dalila Mele, Greta Forlani, Daniela Dalla Gasperina, Mario U. Mondelli, Stefania Varchetta

Subjects: Get full text

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells by Joel Sop, Alicia Mercado, Alexis Figueroa, Tyler P. Beckey, Caroline C. Traut, Li Zhang, Li Zhang, Kellie N. Smith, Kellie N. Smith, Joel N. Blankson

Subjects: Get full text

Partial N-gene target failure in the Seegene Allplex SARS-CoV-2 Master Assay as a proxy of SARS-CoV-2 BA.2.86 by Maria Beatrice Valli, Maria Letizia Schiavone, Martina Rueca, Giulia Berno, Pietro Giorgio Spezia, Cesare Ernesto Maria Gruber, Federica Forbici, Lavinia Fabeni, Daniele Focosi, Enrico Girardi, Marcello Meledandri, Fabrizio Maggi

Subjects: Get full text

The significance of recurrent de novo amino acid substitutions that emerged during chronic SARS-CoV-2 infection: an observational studyResearch in context by Jonathan Daniel Ip, Wing-Ming Chu, Wan-Mui Chan, Allen Wing-Ho Chu, Rhoda Cheuk-Ying Leung, Qi Peng, Anthony Raymond Tam, Brian Pui-Chun Chan, Jian-Piao Cai, Kwok-Yung Yuen, Kin-Hang Kok, Yi Shi, Ivan Fan-Ngai Hung, Kelvin Kai-Wang To

Subjects: Get full text

Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1 by Muhammad Saqib Sohail, Syed Faraz Ahmed, Ahmed Abdul Quadeer, Matthew R. McKay

Subjects: Get full text

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster by Julien Favresse, Constant Gillot, Julien Cabo, Clara David, Jean-Michel Dogné, Jonathan Douxfils

Subjects: Get full text